Furthermore, we compared the tumor mutational burden (TMB) as well as CD8+ T cell, CD4+ T cell, and Treg immune infiltration levels between ERBB2-mutated BC and ERBB2 non-mutated BC via in silico analysis. This evidence concerns the gene ERBB2 and breast cancer.